MA41107A - Compositions anti-cancéreuses - Google Patents

Compositions anti-cancéreuses

Info

Publication number: MA41107A
Authority: MA; Morocco
Prior art keywords: cancer compositions; cancer; compositions
Prior art date: 2014-12-05

Application number

MA041107A

Other languages

English (en)

Other versions

MA41107B1 (fr

Inventor

Dennis Martin Hester

Jason Michael Vaughn

Original Assignee

Aragon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-05

Filing date

2015-12-03

Publication date

2017-10-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41107(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-03 Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc

2017-10-10 Publication of MA41107A publication Critical patent/MA41107A/fr

2025-01-31 Publication of MA41107B1 publication Critical patent/MA41107B1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

MA41107A 2014-12-05 2015-12-03 Compositions anti-cancéreuses MA41107B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP14196594		2014-12-05
PCT/US2015/063661 WO2016090098A1 (fr)	2014-12-05	2015-12-03	Compositions anti-cancéreuses
EP15817641.2A EP3226841B1 (fr)	2014-12-05	2015-12-03	Compositions anticancéreuses

Publications (2)

Publication Number	Publication Date
MA41107A true MA41107A (fr)	2017-10-10
MA41107B1 MA41107B1 (fr)	2025-01-31

Family

ID=52006906

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA41107A MA41107B1 (fr)	2014-12-05	2015-12-03	Compositions anti-cancéreuses

Country Status (29)

Country	Link
US (3)	US20170360754A1 (fr)
EP (2)	EP4494636A3 (fr)
JP (2)	JP6937692B2 (fr)
KR (2)	KR102348320B1 (fr)
CN (2)	CN114886852A (fr)
AR (1)	AR102926A1 (fr)
AU (3)	AU2015358490B2 (fr)
BR (1)	BR112017011788A2 (fr)
CA (1)	CA2969656A1 (fr)
CL (1)	CL2017001371A1 (fr)
CO (1)	CO2017005572A2 (fr)
CR (1)	CR20170216A (fr)
EA (1)	EA201791222A1 (fr)
ES (1)	ES2996833T3 (fr)
HR (1)	HRP20241719T1 (fr)
HU (1)	HUE069689T2 (fr)
IL (2)	IL252323B (fr)
MA (1)	MA41107B1 (fr)
MD (1)	MD3226841T2 (fr)
MX (2)	MX387933B (fr)
NZ (1)	NZ770528A (fr)
PH (1)	PH12017500964A1 (fr)
PL (1)	PL3226841T3 (fr)
RS (1)	RS66323B1 (fr)
SG (1)	SG11201704267VA (fr)
SM (1)	SMT202400518T1 (fr)
TW (2)	TWI754258B (fr)
UA (1)	UA120950C2 (fr)
WO (1)	WO2016090098A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX371020B (es)	2012-09-26	2020-01-13	Aragon Pharmaceuticals Inc	Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico.
US20170360754A1 (en)	2014-12-05	2017-12-21	Aragon Pharmaceuticals, Inc.	Anticancer compositions
KR102387089B1 (ko)	2014-12-05	2022-04-14	아라곤 파마슈티컬스, 인코포레이티드	항암 조성물
SG11202003402QA (en)	2017-10-16	2020-05-28	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2020144649A1 (fr)	2019-01-10	2020-07-16	Aragon Pharmaceuticals, Inc.	Composition pharmaceutique comprenant de l'enzalutamide dispersé dans une compote de pomme
EP3918607A1 (fr)	2019-01-30	2021-12-08	Janssen Pharmaceutica NV	Méthodes de traitement du cancer de la prostate sur la base de sous-types moléculaires
SG11202107712SA (en)	2019-01-30	2021-08-30	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020239478A1 (fr)	2019-05-28	2020-12-03	Pharma Mar, S.A.	Trabectédine pour le traitement de sarcomes basé sur des marqueurs génomiques
EP3811932A1 (fr)	2019-10-22	2021-04-28	Zentiva K.S.	Forme posologique d'apalutamide
EP4054572A1 (fr)	2019-11-04	2022-09-14	Aragon Pharmaceuticals, Inc.	Inhibiteurs du récepteur des androgènes pour le traitement du cancer de la prostate non métastatique résistant à la castration chez des sujets présentant une déficience hépatique grave
WO2021245285A1 (fr)	2020-06-05	2021-12-09	Janssen Pharmaceutica Nv	Méthodes de traitement du cancer de la prostate sur la base de sous-types moléculaires
WO2022049523A1 (fr)	2020-09-04	2022-03-10	Aragon Pharmaceuticals, Inc.	Méthodes de traitement du cancer de la prostate
WO2022195407A1 (fr)	2021-03-19	2022-09-22	Aragon Pharmaceuticals, Inc.	Méthodes de traitement du cancer de la prostate
WO2023122842A1 (fr) *	2021-12-31	2023-07-06	Gador Limitada	Procédé de préparation d'apalutamide, intermédiaires de synthèse et dispersion solide amorphe le contenant
WO2023152611A1 (fr)	2022-02-11	2023-08-17	Aragon Pharmaceuticals, Inc.	Apalutamide et relugolix pour le traitement du cancer de la prostate
WO2023209555A1 (fr)	2022-04-26	2023-11-02	Aragon Pharmaceuticals, Inc.	Produits médicamenteux approuvés et méthodes de traitement du cancer de la prostate
CN116183787A (zh) *	2022-12-26	2023-05-30	郑州德迈药业有限公司	醋酸羟丙甲纤维素琥珀酸酯在阿帕他胺溶出检测中的应用以及检测方法
KR20250157532A (ko)	2023-03-16	2025-11-04	바이엘 컨수머 케어 악티엔게젤샤프트	호르몬 감수성 전립선암의 생화학적 재발이 있는 환자의 치료를 위한 안드로겐 수용체 길항제
WO2025153768A1 (fr) *	2024-01-18	2025-07-24	Nanoform Finland Oyj	Composition contenant de l'apalutamide nanométrique cristallin
WO2025174375A1 (fr) *	2024-02-15	2025-08-21	Aragon Pharmaceuticals, Inc.	Compositions anticancéreuses

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2132449C (fr)	1992-03-31	2002-09-10	Susan E. Barrie	Steroides 17-substitues utilises dans le traitement du cancer
DK0901786T3 (da) *	1997-08-11	2007-10-08	Pfizer Prod Inc	Faste farmaceutiske dispersioner med foröget biotilgængelighed
WO2001060410A1 (fr)	2000-02-21	2001-08-23	Takeda Chemical Industries, Ltd.	Preparations a liberation lente contenant un compose physiologiquement actif peu soluble dans l'eau et methode de production et d'utilisation desdites preparations
EE200300416A (et)	2001-02-27	2003-12-15	Astrazeneca Ab	Ravimvorm
KR20030087048A (ko)	2001-04-02	2003-11-12	아스트라제네카 아베	4-시아노-트리플루오로-3-(4-플루오로페닐설포닐)-2-히드록시-2-메틸프로피오노-ｍ 톨루이다이드 및 ｐｖｐ를포함하는 고체 약학 조성물
SK15732003A3 (sk) *	2001-06-22	2005-01-03	Pfizer Products Inc.	Farmaceutické kompozície zahrnujúce liečivá s nízkou rozpustnosťou a/alebo liečivá citlivé na kyselinu a neutralizované kyslé polyméry
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
MXPA04007435A (es)	2002-02-01	2004-10-11	Pfizer Prod Inc	Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion.
JPWO2003077827A1 (ja)	2002-03-19	2005-07-14	日本新薬株式会社	医薬固体分散体の製造方法
WO2005055987A1 (fr)	2003-12-15	2005-06-23	Council Of Scientific & Industrial Research	Compositions pharmaceutiques au gout masque comportant une medicament amer et un polymere sensible au ph
GB0502790D0 (en)	2005-02-10	2005-03-16	Univ London Pharmacy	Solid dispersion of hydrophobic bioactive
SI1893196T2 (sl)	2005-05-13	2015-10-30	The Regents Of The University Of California	Diarilhidantoinska spojina
DK2004181T6 (da) *	2006-03-27	2023-08-21	Univ California	Androgen receptormodulator til behandling af prostatacancer og androgen receptor-associerede sygdomme
AU2010232670B2 (en)	2009-04-03	2015-07-09	F. Hoffmann-La Roche Ag	Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
EA028869B1 (ru)	2010-02-16	2018-01-31	Арагон Фармасьютикалс, Инк.	Модуляторы рецептора андрогенов и их применение
CN102525876B (zh)	2010-12-15	2014-03-12	西安力邦医药科技有限责任公司	阿司匹林固体分散体、其制备方法、药物组合物和用途
US10071945B2 (en)	2011-06-15	2018-09-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Nuclear receptor modulators and their use for the treatment and prevention of cancer
US20150037407A1 (en)	2012-03-21	2015-02-05	Emphascience, Inc.	Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
WO2013152342A1 (fr) *	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Inhibiteur de mtor anticancéreux et combinaison anti-androgène
PE20200725A1 (es)	2012-06-07	2020-07-21	Aragon Pharmaceuticals Inc	Formas cristalinas del modulador receptor de androgeno: 4-[7-(6-ciano-5-trifluorometilpiridin-3-il)-8-oxo-6-tioxo-5,7-diazaespiro[3,4]oct-5-il]-2-fluoro-n-metilbenzamida) (apalutamida)
US10668156B2 (en)	2012-06-22	2020-06-02	Basf Se	Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
KR102138544B1 (ko) *	2012-08-24	2020-07-28	다우 글로벌 테크놀로지스 엘엘씨	신규한 하이드록시알킬 메틸 셀룰로즈 아세테이트 석시네이트
CA2884795C (fr)	2012-09-11	2023-10-17	Medivation Prostate Therapeutics, Inc.	Formulations d'enzalutamide
US9977033B2 (en)	2012-09-11	2018-05-22	The Board Of Regents Of The University Of Texas System	Methods for assessing cancer recurrence
MX371020B (es) *	2012-09-26	2020-01-13	Aragon Pharmaceuticals Inc	Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico.
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
JP6192244B2 (ja)	2013-01-22	2017-09-06	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	改良されたバイオアベイラビリティを有する薬学的組成物
SG11201507681PA (en)	2013-03-15	2015-10-29	Iceutica Inc	Abiraterone acetate formulation
WO2014167428A2 (fr)	2013-04-10	2014-10-16	Shilpa Medicare Limited	4-(3-(4-cyano-3-(trifluorométhyl)phényl)-5,5-diméthyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-méthylbenzamide amorphe
WO2015023710A1 (fr) *	2013-08-12	2015-02-19	Tokai Pharmaceuticals, Inc.	Biomarqueurs pour le traitement de troubles néoplasiques à l'aide de thérapies ciblant les androgènes
WO2015116696A1 (fr)	2014-01-28	2015-08-06	Massachusetts Institute Of Technology	Thérapies de combinaison et procédés d'utilisation associés pour le traitement du cancer
CA2940984A1 (fr) *	2014-02-05	2015-08-13	Lek Pharmaceuticals D.D.	Compositions pharmaceutiques solides d'antagonistes du recepteur des androgenes
TWI718102B (zh)	2014-08-08	2021-02-11	日商中外製藥股份有限公司	４環性化合物的非晶質體
CA2969661C (fr)	2014-12-05	2023-04-25	Aragon Pharmaceuticals, Inc.	Compositions anticancereuses
KR102387089B1 (ko)	2014-12-05	2022-04-14	아라곤 파마슈티컬스, 인코포레이티드	항암 조성물
US20170360754A1 (en)	2014-12-05	2017-12-21	Aragon Pharmaceuticals, Inc.	Anticancer compositions
JP2019517497A (ja)	2016-06-03	2019-06-24	アラゴンファーマシューティカルズ，インコーポレイテッド	抗癌性組成物
CN111344283B (zh)	2018-06-20	2022-08-12	苏州科睿思制药有限公司	Arn-509的晶型及其制备方法和用途
EP3811932A1 (fr)	2019-10-22	2021-04-28	Zentiva K.S.	Forme posologique d'apalutamide

2015
- 2015-12-03 US US15/533,188 patent/US20170360754A1/en not_active Abandoned
- 2015-12-03 KR KR1020177018239A patent/KR102348320B1/ko active Active
- 2015-12-03 RS RS20241412A patent/RS66323B1/sr unknown
- 2015-12-03 MA MA41107A patent/MA41107B1/fr unknown
- 2015-12-03 JP JP2017529604A patent/JP6937692B2/ja active Active
- 2015-12-03 ES ES15817641T patent/ES2996833T3/es active Active
- 2015-12-03 EA EA201791222A patent/EA201791222A1/ru unknown
- 2015-12-03 PL PL15817641.2T patent/PL3226841T3/pl unknown
- 2015-12-03 SM SM20240518T patent/SMT202400518T1/it unknown
- 2015-12-03 KR KR1020207035390A patent/KR20200141533A/ko not_active Ceased
- 2015-12-03 MX MX2017007203A patent/MX387933B/es unknown
- 2015-12-03 WO PCT/US2015/063661 patent/WO2016090098A1/fr not_active Ceased
- 2015-12-03 MD MDE20170152T patent/MD3226841T2/ro unknown
- 2015-12-03 AU AU2015358490A patent/AU2015358490B2/en active Active
- 2015-12-03 EP EP24202355.4A patent/EP4494636A3/fr active Pending
- 2015-12-03 HR HRP20241719TT patent/HRP20241719T1/hr unknown
- 2015-12-03 NZ NZ770528A patent/NZ770528A/en unknown
- 2015-12-03 CN CN202210133724.8A patent/CN114886852A/zh active Pending
- 2015-12-03 CR CR20170216A patent/CR20170216A/es unknown
- 2015-12-03 UA UAA201707020A patent/UA120950C2/uk unknown
- 2015-12-03 SG SG11201704267VA patent/SG11201704267VA/en unknown
- 2015-12-03 CN CN201580066233.4A patent/CN106999431B/zh active Active
- 2015-12-03 CA CA2969656A patent/CA2969656A1/fr active Pending
- 2015-12-03 BR BR112017011788A patent/BR112017011788A2/pt not_active Application Discontinuation
- 2015-12-03 EP EP15817641.2A patent/EP3226841B1/fr active Active
- 2015-12-03 HU HUE15817641A patent/HUE069689T2/hu unknown
- 2015-12-04 TW TW109112959A patent/TWI754258B/zh active
- 2015-12-04 TW TW104140822A patent/TWI702966B/zh active
- 2015-12-04 AR ARP150103982A patent/AR102926A1/es not_active Application Discontinuation
2017
- 2017-05-16 IL IL252323A patent/IL252323B/en active IP Right Grant
- 2017-05-25 PH PH12017500964A patent/PH12017500964A1/en unknown
- 2017-05-29 CL CL2017001371A patent/CL2017001371A1/es unknown
- 2017-06-05 CO CONC2017/0005572A patent/CO2017005572A2/es unknown
- 2017-06-05 MX MX2021013965A patent/MX2021013965A/es unknown
2020
- 2020-04-23 JP JP2020076516A patent/JP7174006B2/ja active Active
- 2020-12-29 IL IL279833A patent/IL279833B/en unknown
2021
- 2021-03-30 AU AU2021201979A patent/AU2021201979B2/en active Active
2023
- 2023-03-29 US US18/192,244 patent/US20230233529A1/en not_active Abandoned
- 2023-05-02 AU AU2023202710A patent/AU2023202710A1/en not_active Abandoned
2024
- 2024-05-10 US US18/660,698 patent/US12303493B2/en active Active

Also Published As

Publication number	Publication date
EA201791222A1 (ru)	2017-09-29
MX387933B (es)	2025-03-19
TWI702966B (zh)	2020-09-01
AU2021201979A1 (en)	2021-04-29
TW201630592A (zh)	2016-09-01
CL2017001371A1 (es)	2018-01-05
CN114886852A (zh)	2022-08-12
IL252323B (en)	2021-04-29
SMT202400518T1 (it)	2025-01-14
TWI754258B (zh)	2022-02-01
EP4494636A3 (fr)	2025-04-30
CR20170216A (es)	2017-08-30
MX2017007203A (es)	2017-08-28
PH12017500964A1 (en)	2017-10-18
CN106999431B (zh)	2022-03-04
ES2996833T3 (en)	2025-02-13
CA2969656A1 (fr)	2016-06-09
AU2015358490A1 (en)	2017-06-08
BR112017011788A2 (pt)	2017-12-26
UA120950C2 (uk)	2020-03-10
MA41107B1 (fr)	2025-01-31
AR102926A1 (es)	2017-04-05
MX2021013965A (es)	2022-01-04
US20240293374A1 (en)	2024-09-05
CN106999431A (zh)	2017-08-01
US20170360754A1 (en)	2017-12-21
HUE069689T2 (hu)	2025-04-28
KR20200141533A (ko)	2020-12-18
EP4494636A2 (fr)	2025-01-22
KR20170086656A (ko)	2017-07-26
JP7174006B2 (ja)	2022-11-17
JP2017536398A (ja)	2017-12-07
EP3226841A1 (fr)	2017-10-11
NZ731963A (en)	2024-03-22
IL252323A0 (en)	2017-07-31
CO2017005572A2 (es)	2017-09-20
EP3226841B1 (fr)	2024-10-09
SG11201704267VA (en)	2017-06-29
US20230233529A1 (en)	2023-07-27
NZ770528A (en)	2024-03-22
WO2016090098A1 (fr)	2016-06-09
IL279833B (en)	2022-03-01
US12303493B2 (en)	2025-05-20
RS66323B1 (sr)	2025-01-31
PL3226841T3 (pl)	2025-03-03
TW202031248A (zh)	2020-09-01
JP6937692B2 (ja)	2021-09-22
HRP20241719T1 (hr)	2025-02-14
AU2023202710A1 (en)	2023-05-18
EP3226841C0 (fr)	2024-10-09
JP2020143069A (ja)	2020-09-10
MD3226841T2 (ro)	2025-06-30
AU2021201979B2 (en)	2023-02-02
IL279833A (en)	2021-01-31
KR102348320B1 (ko)	2022-01-10
AU2015358490B2 (en)	2021-04-08

Publication	Publication Date	Title
SMT202400518T1 (it)	2025-01-14	Composizioni anticancro
DK3361870T3 (da)	2020-05-11	Fungicidsammensætninger
DK3542812T3 (da)	2021-04-12	Glycopeptidsammensætninger
DK3151672T3 (da)	2021-02-01	Forbedrede t-celle-sammensætninger
DK3140008T3 (da)	2019-06-24	Hurtigtvirkende insulinsammensætninger
DK3130649T3 (da)	2025-02-03	Haloolefin-baseret sammensætning
LT3240415T (lt)	2022-10-10	Fungicidinės kompozicijos
DK3089741T3 (da)	2021-06-07	Farmaceutiske sammensætninger omfattende azd9291
LT3226842T (lt)	2021-03-25	Priešvėžinės kompozicijos
LT3226843T (lt)	2021-08-10	Priešvėžinės kompozicijos
FR3024363B1 (fr)	2018-08-10	Composition thermogelifiable
BR112017001922A2 (pt)	2018-07-17	composições fungicidas
PL3034554T3 (pl)	2021-02-22	Kompozycje poliamidowe
DK3250182T3 (da)	2023-06-26	Dispergible sammensætninger
DK3334726T3 (da)	2022-05-16	Plinabulinsammensætninger
PL3015500T3 (pl)	2019-09-30	Kompozycje poliamidowe
PL2924070T3 (pl)	2017-10-31	Kompozycje poliamidów
MA45090A (fr)	2021-04-28	Compositions anticancéreuses
DK3129007T3 (da)	2020-11-02	Vaccinesammensætninger
CL2017000639A1 (es)	2018-01-26	Composición
DK3322295T3 (da)	2022-12-19	Sammensætning
DK3215127T3 (da)	2021-02-01	Sammensætninger omfattende cyclosporin
DK3316857T3 (da)	2021-10-18	Multifasiske sammensætninger
DK3393254T3 (da)	2021-07-26	Sammensætning
HUE070090T2 (hu)	2025-05-28	Összetétel